Characterization and Management of Cytokine Release Syndrome From the MonumenTAL-1 Study of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma
[Introduction] Cytokine release syndrome (CRS) is a common adverse event associated with T-cell redirection therapies (TCRT), including talquetamab, the first GPRC5D × CD3 bispecific antibody approved for relapsed/refractory multiple myeloma (RRMM). We describe CRS with talquetamab and implications for clinical practice.
Authors
- Sheri Skerget (ORCID: https://orcid.org/0000-0001-5153-0835)
- Brandi Hilder
- Thomas Renaud (ORCID: https://orcid.org/0000-0002-4895-6090)
- Tara Masterson (ORCID: https://orcid.org/0000-0001-8061-3576)
- Jaszianne Tolbert
- Raluca Verona (ORCID: https://orcid.org/0000-0003-0044-4341)
- Christoph Heuck
- Brea Lipe (ORCID: https://orcid.org/0000-0002-7596-2015)
- Jue Gong (ORCID: https://orcid.org/0009-0007-1599-1440)
- Indrajeet Singh (ORCID: https://orcid.org/0000-0002-0062-6965)
- Leo Rasche
- Ajai Chari
- Amrita Krishnan
- Niels W. C. J. van de Donk
- Thomas Martin
- Jing Christine Ye
- Deeksha Vishwamitra
- Rakesh Popat
- M. Damiette Smit
- César Rodríguez
- Carolina Schinke
- Michela Campagna
- Maria Victoria Mateos
Publication Details
- Journal
- DIGITAL.CSIC (Spanish National Research Council (CSIC))
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1002/cam4.71276digital
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00